Rare Disease Report
60th ASH Annual Meeting & Exposition

60th ASH Annual Meeting & Exposition

Mohamad Mohty, MD, PhD, discusses the investigational therapy cytotoxic T lymphocytes (CTLs) therapy for the treatment of Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBVPTLD). 
An early prophylaxis in combination with an assistant device like myPKFit can improve the outcomes of treatment.
This rare leukemia form may be treated with ruxolitinib, which appears to be well-tolerated by patients.
Patients with myeloproliferative neoplasms (MPN) with essential thrombocythemia (ET) or polycythemia vera (PV) were found to benefit from hydroxyurea therapy. 
Patients with myeloid/lymphoid neoplasms enrolled in the phase 2 clinical trial demonstrated pemigatinib was generally well-tolerated.  
Nizar Bahlis, MD, highlights the phase 3 POLLUX trial evaluating daratumumab plus lenalidomide and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma. 
Among the highlights, significant and sustained increases in hemoglobin without transfusions stood out. 
Lead investigator, John Leonard, MD, reviews the phase 3 AUGMENT trial investigating lenalidomide plus rituximab for the treatment of relapsed/refractory follicular lymphoma. 
Models show that for every gram of hemoglobin increased per deciliter, the risks associated with hemolytic anemia decrease.
Jorge Cortes, MD, highlights the phase 3 QuANTUM-R trial results and explains their clinical implications for patients with FLT3-ITD-mutated relapsed/refractory acute myeloid leukemia (AML). 
Copyright © RareDR 2013-2019 Rare Disease Communications. All Rights Reserved.